TaiRx, a biopharmaceutical company, is progressing on two fronts: new drug development and health products. Following the U.S. FDA orphan drug designation granted to its small-molecule anticancer drug CVM-1118, the company has attracted multiple international pharmaceutical companies for partnership discussions. The next step involves initiating multinational, multi-center clinical trials targeting neuroendocrine tumors (NET) in collaboration with major industry players. Meanwhile, the selenium injection and health supplement businesses continue to expand, with a flagship health product scheduled for a major launch in mid-August and a high-dose packaging version of the selenium injection “Xiningte” planned for release next year.
At the recently concluded 2025 North America Biotechnology Conference, TaiRx actively engaged with over 20 international pharmaceutical and biotech companies. The company’s promotion focused on CVM-1118, which received orphan drug status from the FDA earlier this year, significantly enhancing its appeal for licensing negotiations.
CVM-1118 has already begun clinical trial design for the NET indication and is in communication with the FDA. There is strong potential for collaboration with partners to launch multinational, multi-center trials. Regarding liver cancer indications, TaiRx is also in talks with several major Chinese pharmaceutical companies, opening up strategic cooperation and early-stage opportunities ahead of planned clinical trials in China by year-end.
TaiRx is developing an antibody-drug conjugate (ADC) using the active metabolite of CVM-1118 as the payload. This innovative payload design offers a dual mechanism: inducing tumor cell apoptosis while inhibiting cancer metastasis, a rare multifunctional approach in the market. Animal studies demonstrated complete tumor eradication after three consecutive weeks of dosing, highlighting its promising anticancer efficacy. This novel payload platform has attracted international pharma interest, and TaiRx plans to collaborate with partners who hold patented antibodies and conjugation technologies to aggressively expand in the global ADC market, exploring various options including technology transfer and joint development.
Additionally, TaiRx has officially launched a dual-axis strategy of “pharmaceuticals × consumer health,” advancing selenium injection drugs alongside health supplements to capture both clinical and mass markets. Since its launch, the selenium injection “Xiningte” has achieved a compound annual growth rate exceeding 32%. Increased awareness of selenium’s health benefits in the medical community and general public has driven explosive sales growth, with first-half 2025 revenues surpassing the total revenue for 2024. Strong market demand is expected to continue in the second half of the year.
Beyond the original 2 mL formulation, “Xiningte” has received Ministry of Health approval for a new 10 mL high-dose packaging, slated for release in Q1 2026. TaiRx has partnered with leading domestic infusion product manufacturer Sin Dong Biotech, which will handle domestic distribution of the 10 mL version, expanding clinical applications across medical specialties. Leveraging Sin Dong Biotech’s overseas market expertise, TaiRx is also initiating plans for international pharmaceutical product deployment.
TaiRx’s proprietary health supplement “Selite” will debut under a new consumer brand “Hao Xi Jia,” aiming to develop a comprehensive line of selenium-based health products using premium active selenium raw materials. This marks the company’s formal entry into the B2C market and mainstream retail channels. The inaugural health product under this brand is set for a high-profile launch in mid-August, offering new health supplement options to the public.
Resource: 台睿生技新藥與保健雙軌並進，國際合作全面開展
